Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 59 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemorrhagic Shock Clear all
Terminated Phase 2 Interventional

Emergency Preservation and Resuscitation (EPR) for Cardiac Arrest From Trauma

NCT01042015
View directory record Official record
Conditions
Cardiac Arrest From Trauma
Interventions
Emergency preservation and resuscitation, Standard resuscitation
Combination Product · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)

NCT00973102
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Premarin IV, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of HBV-001 D1 in Healthy Adults

NCT00936429
View directory record Official record
Conditions
Dengue Fever
Interventions
DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel), Placebo for DEN1-80E
Biological
Lead sponsor
Hawaii Biotech, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 1, 2026, 6:27 PM EDT
Withdrawn Phase 2 Interventional

Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMM

NCT06352866
View directory record Official record
Conditions
Multiple Myeloma, Cytokine Release Syndrome, Refractory Multiple Myeloma, Immune Effector Cell Associated Neurotoxicity Syndrome
Interventions
Siltuximab, Teclistamab(FDA-approved)
Drug
Lead sponsor
Jack Khouri, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 1, 2026, 6:27 PM EDT
Not listed Phase 3 Interventional

Safety and Efficacy of PolyHeme(R) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-Hospital Setting

NCT00076648
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Poly SFH-P Injection
Drug
Lead sponsor
Northfield Laboratories
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
32
States / cities
San Diego, California • Denver, Colorado • Newark, Delaware + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2006 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Phase 2 Interventional Results available

Control of Major Bleeding After Trauma Study

NCT01838863
View directory record Official record
Conditions
Trauma, Hemorrhagic Shock
Interventions
Type AB plasma, Crystalloid fluid (standard of care for resuscitation)
Biological · Drug
Lead sponsor
Denver Health and Hospital Authority
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Not applicable Interventional Results available

Feasibility of Evaluating XSTAT Use in the Prehospital Setting

NCT04663087
View directory record Official record
Conditions
Shock, Hemorrhagic, Injury Penetrating, Hemorrhage
Interventions
XSTAT, Standard of Care
Device · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 30, 2024 · Synced Oct 1, 2026, 6:27 PM EDT
Not yet recruiting No phase listed Observational

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

NCT07218185
View directory record Official record
Conditions
Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated No phase listed Observational

A 48 Subject Study Using Non-invasive Multi-Technology Measurements for Early Detection of Ongoing Hemorrhage

NCT04814810
View directory record Official record
Conditions
Occult Bleeding, Hemorrhage, Hemorrhagic Shock
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated No phase listed Observational

Hypertonic Modulation of Inflammation Following Injury

NCT00750997
View directory record Official record
Conditions
Hemorrhagic Shock, Traumatic Brain Injury
Interventions
hypertonic saline
Drug
Lead sponsor
University of Washington
Other
Eligibility
15 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 1, 2017 · Synced Oct 1, 2026, 6:27 PM EDT
Completed No phase listed Observational

Vasopressin Deficiency in Hemorrhagic Shock

NCT01107314
View directory record Official record
Conditions
Body Response to Trauma
Interventions
Phlebotomy
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 98 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Phase 2 Interventional

Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma

NCT07657312
View directory record Official record
Conditions
Cytokine Release Syndrome, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Infliximab, Positron Emission Tomography, Talquetamab, Teclistamab, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Naresh Bumma
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Phase 3 Interventional

Massive Transfusion in Children-2: A Trial Examining Life Threatening Hemorrhage in Children

NCT06070350
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma Injury
Interventions
Low Titer Group O Whole Blood (LTOWB), Placebo, Tranexamic Acid (TXA), Component Therapy (CT)
Biological · Drug
Lead sponsor
Philip Spinella
Other
Eligibility
Up to 17 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume

NCT01935427
View directory record Official record
Conditions
Hemorrhage
Interventions
Not listed
Lead sponsor
Flashback Technologies
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Not applicable Interventional Results available

Biological Response of Trauma Patients to Standard Trauma Resuscitation Therapy

NCT01239680
View directory record Official record
Conditions
Hemorrhagic Shock
Interventions
Glutamine, Ringer's Lactate, Placebo (for Glutamine)
Drug
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
21 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
2
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 17, 2014 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 2 Interventional Results available

Cold Stored Platelet in Hemorrhagic Shock

NCT04667468
View directory record Official record
Conditions
Trauma, Hemorrhage
Interventions
Cold Stored Platelets (CSP), Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
15 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Jackson, Mississippi + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 1, 2026, 6:27 PM EDT
Not listed Phase 2 Interventional

Prehospital Kcentra for Hemorrhagic Shock

NCT04019015
View directory record Official record
Conditions
Trauma Injury
Interventions
Prothrombin Complex Concentrate, Human, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Oct 1, 2026, 6:27 PM EDT
Withdrawn Not applicable Interventional

Philadelphia Immediate Transport in Penetrating Trauma Trial

NCT02821364
View directory record Official record
Conditions
Hemorrhagic Shock, Peritonitis
Interventions
Advanced Life Support
Other
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Type O Whole Blood and Assessment of Age During Prehospital Resuscitation Trial

NCT04684719
View directory record Official record
Conditions
Hemorrhagic Shock, Traumatic Injury
Interventions
low titer whole blood, Standard Care
Biological
Lead sponsor
Jason Sperry
Other
Eligibility
18 Years to 89 Years
Enrollment
1,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Birmingham, Alabama • Louisville, Kentucky • Jackson, Mississippi + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Completed Phase 3 Interventional

Trauma Resuscitation With Low-Titer Group O Whole Blood or Products

NCT05638581
View directory record Official record
Conditions
Wounds and Injuries, Shock, Hemorrhagic
Interventions
LTOWB, Components
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
15 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 1, 2026, 6:27 PM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Tolerability of Valproic Acid in Trauma Patients(Part 2)

NCT02872428
View directory record Official record
Conditions
Shock,Hemorrhagic, Trauma
Interventions
Valproic Acid, Isotonic saline solution
Drug
Lead sponsor
Dr. Hasan Alam
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 1, 2026, 6:27 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Pre-Hospital Use of Plasma for Traumatic Hemorrhage

NCT02303964
View directory record Official record
Conditions
Shock, Hemorrhagic
Interventions
Plasma, Normal saline
Biological · Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2016 · Synced Oct 1, 2026, 6:27 PM EDT
Not listed Not applicable Interventional

A Comparison of Two Target Mean Arterial Pressures in the Resuscitation of Hypotensive Trauma Patients

NCT00459160
View directory record Official record
Conditions
Hemorrhagic Shock, Trauma, Wounds, Penetrating, Shock, Traumatic, Multiple Trauma
Interventions
Intraoperative Hypotensive Resuscitation
Procedure
Lead sponsor
Baylor College of Medicine
Other
Eligibility
12 Years to 45 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2010 · Synced Oct 1, 2026, 6:27 PM EDT
Recruiting Phase 4 Interventional

Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)

NCT07609940
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Los Angeles, California • St. Petersburg, Florida • Baton Rouge, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 1, 2026, 6:27 PM EDT